Drug Trial Radar · NCT03538028
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
Last checked: Nov 20, 2026Latest source record: Oct 30, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
22
Actual
Start
Jun 18, 2018
Primary completion
Oct 7, 2020
Study completion Oct 7, 2020
Sponsor
- Lead sponsor
- Incyte Biosciences International SàrlIncyte (INCY)
- Sponsor type
- Industry
- First posted
- May 25, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02385 in participants with advanced malignancies.
Conditions
- Cervical Cancer
- Microsatellite Instability (MSI)-High Endometrial Cancer
- Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ])
- Esophageal Cancer
- Hepatocellular Carcinoma
- Melanoma (Uveal Melanoma Excluded)
- Merkel Cell Carcinoma
- Mesothelioma
- MSI-high Colorectal Cancer
- Non-small Cell Lung Cancer (NSCLC)
- Ovarian Cancer
- Squamous Cell Carcinoma of the Head and Neck (SCCHN)
- Small Cell Lung Cancer (SCLC)
- Renal Cell Carcinoma (RCC)
- Triple-negative Breast Cancer
- Urothelial Carcinoma
- Diffuse Large B-cell Lymphoma
Interventions
INCAGN02385Biological
INCAGN02385 administered as an intravenous infusion over 30 minutes.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of treatment-emergent adverse events (TEAEs)Time frame: Up to 12 months
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
The Angeles Clinic and Research Center
Los Angeles, California
Hackensack Medical Center
Hackensack, New Jersey
Carolina BioOncology Institute
Huntersville, North Carolina
Vanderbilt University Medical Center
Nashville, Tennessee
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.